Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease.
about
Role of aggressive surgical cytoreduction in advanced ovarian cancerThe effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis.Blood type, ABO genetic variants, and ovarian cancer survival.Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective studyNeoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.High-prevalence and broad spectrum of Cell Adhesion and Extracellular Matrix gene pathway mutations in epithelial ovarian cancer.Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancerMetabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy.Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records.Radical surgery in ovarian cancer.Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer.MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression.Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer.Relationship between initiation time of adjuvant chemotherapy and survival in ovarian cancer patients: a dose-response meta-analysis of cohort studies.Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?Asian Society of Gynecologic Oncology International Workshop 2014.A Review of Thoracic and Mediastinal Cytoreductive Techniques in Advanced Ovarian Cancer: Extending the Boundaries.Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.Rectosigmoidian Involvement in Advanced-stage Ovarian Cancer - Intraoperative Decisions.Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer.Transvaginal Ultrasound-Guided Core Needle Biopsy of Pelvic Masses.ICG-fluorescence imaging for detection of peritoneal metastases and residual tumoral scars in locally advanced ovarian cancer: A pilot study.Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.Which Surgical Attitude to Choose in the Context of Non-Resectability of Ovarian Carcinomatosis: Beyond Gross Residual Disease Considerations.Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer
P2860
Q26801358-1B6E212D-9088-4165-9EDA-9FC907ED9832Q30249773-58B7AEB7-77C0-48AC-A72C-EFD0CDDD9D54Q33610639-23B214FC-4A0F-4149-B881-33B9C2412407Q33735142-4645DD4B-6006-4B8B-AF0C-905FF1C811FCQ33816983-9FD45DB9-CA3E-456F-8D4A-D764961473B9Q33910179-8618EF6A-556B-40B9-991A-01715D975428Q34389383-ABECE5BC-217C-4B49-963D-0564481C5D7DQ36295211-E51FF2A4-664A-4DA0-AF64-CF2575521CB3Q36380325-913A89DB-8A1A-4733-86D3-79E84AF3F1B8Q36474863-762816F2-75FE-46CD-92AF-6960573627F1Q36801193-1EB9A03C-2F1D-4A4F-858A-5C34940BF4E8Q36866311-1B83C08E-8589-440F-8064-19F13C522250Q38364615-94A38EFC-D14F-43B4-9461-D1CE2F0484BBQ38600645-86F0D73A-7D8B-4363-BECB-C9C5E8482702Q38803584-6D83EC82-199B-4937-81BA-A070B5D6BF38Q39256449-DBABBD4B-9125-472F-9602-BC7422FB2CD1Q39816077-68CA5B78-998B-441C-B79C-4256C25EDADCQ40069760-975CC5C2-A5D9-482A-BCB1-6E31572D4862Q40332287-0DBD4247-9D1D-4B0A-8E35-56B08569EB13Q40485803-00560E9F-9705-489E-B00C-AAE59EAC7D93Q43114850-E3D0DD87-378E-4ABE-8BF6-99F6A603B991Q43114858-397BA914-1E1A-493A-BFAE-40955B5EC39BQ43937948-E7FA693F-8BA4-4093-8B2E-076294E79E1FQ45906655-1401D47A-8A76-41D0-9A07-514118F57F96Q46325180-F5616C4B-5A2D-4741-946E-824C29949C81Q47142905-41A89DFE-01E9-4734-BD5F-388C68417F95Q47279109-B6B86E74-1C50-4CB3-BF42-15D88C90E088Q48103594-F66530F6-279F-48C2-BE37-A1C2D1C0FE2AQ48272417-A6225160-EDA8-44EE-A41C-D4E13A702831Q52886435-4E413500-BE80-48D5-949D-FFAC326EA77FQ53287200-FF5EFFEC-73E4-4A3E-930B-98333FF6B99DQ57210147-CA3E8D42-7C17-419D-95F8-4770866049B9
P2860
Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Evolution of surgical treatmen ...... ng 'optimal' residual disease.
@en
Evolution of surgical treatmen ...... ng 'optimal' residual disease.
@nl
type
label
Evolution of surgical treatmen ...... ng 'optimal' residual disease.
@en
Evolution of surgical treatmen ...... ng 'optimal' residual disease.
@nl
prefLabel
Evolution of surgical treatmen ...... ng 'optimal' residual disease.
@en
Evolution of surgical treatmen ...... ng 'optimal' residual disease.
@nl
P1433
P1476
Evolution of surgical treatmen ...... ing 'optimal' residual disease
@en
P2093
Robert E Bristow
P304
P356
10.1016/J.YGYNO.2012.02.024
P407
P577
2012-02-23T00:00:00Z